Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are attractive targets for anti-angiogenic therapy to reduce obesity as they play an important role in adipose angiogenesis (6, 7). This evidence concerns the gene VEGFA and obesity due to melanocortin 4 receptor deficiency.